literature

HIV mutation literature information.

Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice.

PMID: 18043758 2007 PloS one

Method: The AZT-resistant (M41L, T215Y) R5X4 clinical HIV-1 isolate JD was kindly provided by Mike McCune and prepared by cocultivation of patient peripheral blood mononuclear cells (PBMCs) and expansion in phytohemagglutinin (PHA)-activated PBMCs.

N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.

PMID: 18052601 2007 PLoS medicine

Method: The M41L, L210W, T215Y, and N348I mutations were introduced into WT HIV-1LAI RT by site-directed mutagenesis using the QuikChange Mutagenesis kit.

Method: The analysis was performed for N348I and for each of the TAMs: M41L, D67N, K70R, L210W, T215Y/F, and K219Q/E.

Result: Accordingly, we compared the AZT susceptibility of HIV-1 containing M184V and TAMs (M41L and T215Y) (NL/2AZT + 184) and HIV-1 containing M184V

[Resistance to anti-retroviral therapy in Chilean patients with HIV-1 from 2002 to 2005].

PMID: 18180829 2007 Revista medica de Chile

Abstract: The most common mutations found were T215Y (46%), L10F (44%), Ml84V (3896), K103N (35%) and M41L (32%).

[Study on genotypic resistance mutations to antiretroviral drugs on HIV strains of treated and treatment-naive HIV-1 infectious patients in Hubei province].

PMID: 18396668 2007 Zhonghua liu xing bing xue za zhi

Abstract: Some protease (PR) drug-resistant mutations were found in these samples, such as D30N (2.27%), D30G (2.27%), M46I (4.55%), M46N (2.27%), I47V (4.55%), I84V (4.55%), I84L (2.27%), N88S (2.27%) and L90S (2.27%) that all belonged to major drug-resistant but A71T (29.55%) belonged to minor resistance mutations Five treated patients were detected having mutations associated RT drug resistance: M41L (5.26%), A62V (5.26%),D67N (5.26%),

PMID: 16332398 2006 Virus research

Abstract: Principal antiretroviral resistance mutations (ARM) were observed in 3% of the samples, two cases with K103N and one with M41L, L210W and T215Y, all in HIV-1 clade B infected men.

Influence of naturally occurring insertions in the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase on polymerase fidelity and mutation frequencies in vitro.

PMID: 16432030 2006 The Journal of general virology

Abstract: M41L and T215Y) or an A62V mutation and confers resistance to multiple nucleoside analogue inhibitors.

Abstract: T69S-AG, T69S-SG and T69S-SS alone, in combination with 3'-azido-2',3'-deoxythymidine-resistance mutations M41L, L210W, R211K, L214F, T215Y (LAG(AZ) and LSG(AZ)) or with an alternate set where A62V substitution replaces M41L (VAG(AZ), VSG(AZ) and VSS(AZ)).

In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection.

PMID: 16436719 2006 Antimicrobial agents and chemotherapy

Abstract: SPD754 susceptibility was reduced 1.2- to 2.2-fold against isolates resistant to zidovudine (M41L, T215Y/F, plus a median of three additional nucleoside analogue mutations [NAMs]) and/or lamivudine (M184V) and was reduced 1.3- to 2.8-fold against isolates resistant to abacavir (L74V, Y115F, and M184V plus one other NAM) or stavudine (V75T/M, M41L, T215F/Y, and four other NAMs).

In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.

PMID: 16472877 2006 Antiviral research

Abstract: Interestingly, HIV-1 variants constructed to contain the T215Y zidovudine (AZT)-resistance associated substitution with CPV-resistance associated substitutions V106A, Y181C, F227C, F227L, L234I or V106A/F227L demonstrated 2.4-5.4-fold increased susceptibility to CPV.

Abstract: Results also demonstrate that the CPV-resistance associated substitutions Y181C, F227C, F227L and L234I reverse the phenotypic resistance to AZT conferred by the T215Y substitution.

An additive/subtractive genotypic score as a determinant of the virological response to didanosine in HIV-1 infected patients.

PMID: 16513416 2006 Journal of clinical virology

Abstract: RESULTS: Changes at three codons (M41L, L210W, T215Y/F/D/C/E) were associated with a worse VR and three mutations (K70R, M184V, K219Q) with a better VR.

Abstract: The strongest association with the VR was obtained with the score M41L+L210W+T215Y/F/D/C/E-K70R-K219Q.

Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors.

PMID: 16603849 2006 AIDS (London, England)

Abstract: CONCLUSION: Different combinations of V118I, H208Y, and T215Y produce NNRTI hypersusceptibility.

Abstract: In addition, H208Y/T215Y, V118I/T215Y, and V118I/H208Y/T215Y were hypersusceptible to delavirdine and nevirapine.

Abstract: RESULTS: The single mutations V118I, H208Y, and T215Y did not show hypersusceptibility to efavirenz with mean fold-change of 0.58, 0.55, and 0.70, respectively (P < 0.01 and P = 0.12).

Filtrator